PL3096798T3 - Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego - Google Patents

Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego

Info

Publication number
PL3096798T3
PL3096798T3 PL15740774T PL15740774T PL3096798T3 PL 3096798 T3 PL3096798 T3 PL 3096798T3 PL 15740774 T PL15740774 T PL 15740774T PL 15740774 T PL15740774 T PL 15740774T PL 3096798 T3 PL3096798 T3 PL 3096798T3
Authority
PL
Poland
Prior art keywords
binding proteins
plasma kallikrein
hereditary angioedema
kallikrein binding
treating hereditary
Prior art date
Application number
PL15740774T
Other languages
English (en)
Inventor
Yung CHYUNG
Daniel J. Sexton
Christopher Tenhoor
Jon A. Kenniston
Ryan Faucette
Ryan Iarrobino
Joseph BIEDENKAPP
Burt Adelman
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL3096798T3 publication Critical patent/PL3096798T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
    • C12Y207/03002—Creatine kinase (2.7.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL15740774T 2014-01-21 2015-01-21 Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego PL3096798T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461929716P 2014-01-21 2014-01-21
US201461944361P 2014-02-25 2014-02-25
US201462021397P 2014-07-07 2014-07-07
PCT/US2015/012212 WO2015112578A1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
EP15740774.3A EP3096798B1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Publications (1)

Publication Number Publication Date
PL3096798T3 true PL3096798T3 (pl) 2021-07-26

Family

ID=53681890

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15740774T PL3096798T3 (pl) 2014-01-21 2015-01-21 Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego

Country Status (18)

Country Link
US (2) US11084884B2 (pl)
EP (2) EP3848057B1 (pl)
JP (4) JP6845012B2 (pl)
KR (3) KR102424183B1 (pl)
CN (2) CN106132442B (pl)
AU (3) AU2015209481C1 (pl)
BR (1) BR112016016916B1 (pl)
CA (1) CA2937329C (pl)
DK (1) DK3096798T3 (pl)
EA (1) EA038532B1 (pl)
ES (1) ES2856076T3 (pl)
IL (3) IL246864B (pl)
MX (2) MX387753B (pl)
NZ (2) NZ723369A (pl)
PL (1) PL3096798T3 (pl)
PT (1) PT3096798T (pl)
WO (1) WO2015112578A1 (pl)
ZA (2) ZA201605342B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181419T1 (hr) 2010-01-06 2018-11-16 Dyax Corp. Plazma kalikrein vezni proteini
IL269565B2 (en) * 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
JP6444315B2 (ja) 2013-01-20 2018-12-26 ダイアックス コーポレーション ブラジキニン媒介障害の評価および治療
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
KR102665705B1 (ko) 2013-10-21 2024-05-14 다케다 파머수티컬 컴패니 리미티드 자가면역 질환의 진단 및 치료
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
CN106132442B (zh) 2014-01-21 2023-07-14 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
AU2016243160B2 (en) * 2015-03-30 2022-02-24 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
EP3365685B1 (en) 2015-10-19 2020-11-25 Dyax Corp. Immunoassay to detect cleaved high molecular weight kininogen
WO2017100679A1 (en) * 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2018053260A1 (en) 2016-09-16 2018-03-22 Dyax Corp. Rna biomarkers for hereditary angioedema
AU2017325983B2 (en) * 2016-09-16 2023-12-07 Takeda Pharmaceutical Company Limited Protein biomarkers for diseases associated with the contact activation system
WO2019079496A2 (en) * 2017-10-18 2019-04-25 Regenxbio, Inc. FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3718572B1 (en) 2017-12-01 2024-07-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
JP7261494B2 (ja) 2017-12-01 2023-04-20 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
EP3719128B1 (en) 2017-12-01 2025-01-15 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
JP7436030B2 (ja) 2017-12-29 2024-02-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 複合体及びその調製方法と使用
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
TW202100561A (zh) * 2019-03-14 2021-01-01 美商戴氏公司 血漿胰舒血管素抑制劑及其於治療遺傳性血管水腫發作的用途
CN118256498A (zh) 2019-05-22 2024-06-28 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
EP3992290A4 (en) * 2019-05-24 2023-11-15 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0296171A4 (en) 1986-03-03 1989-11-07 Brigham & Womens Hospital ASSESSMENT PROCEDURE FOR NEPHROTOXICITY.
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69533472T2 (de) 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
PT1941867E (pt) 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
WO2005075665A2 (en) 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
SI2374472T1 (sl) 2006-03-16 2018-11-30 Dyax Corp., Sestavki in postopki za zdravljenje oftalmoloških motenj
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
CA2693921A1 (en) * 2007-07-20 2009-01-29 Genesys Venture Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
JP2010536883A (ja) 2007-08-23 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
EP2313109A2 (en) 2008-07-02 2011-04-27 Emergent Product Development Seattle, LLC Il6 immunotherapeutics
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
HRP20181419T1 (hr) 2010-01-06 2018-11-16 Dyax Corp. Plazma kalikrein vezni proteini
IL269565B2 (en) * 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
LT2704742T (lt) 2011-05-02 2017-10-25 Millennium Pharmaceuticals, Inc. Anti-alfa4beta7 antikūno kompozicija
AU2013221635B2 (en) 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
KR102209796B1 (ko) 2013-01-20 2021-01-29 다이액스 코포레이션 pKal 매개 장애의 평가, 검정 및 치료
JP6444315B2 (ja) 2013-01-20 2018-12-26 ダイアックス コーポレーション ブラジキニン媒介障害の評価および治療
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
CN106132442B (zh) 2014-01-21 2023-07-14 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
AU2016243160B2 (en) 2015-03-30 2022-02-24 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
KR20250030022A (ko) * 2016-09-16 2025-03-05 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커
EP3678551B1 (en) 2017-09-05 2023-06-28 Sanolla Ltd Electronic stethoscope with enhanced features
BR112021003789A2 (pt) 2018-08-30 2021-05-18 Dyax Corp. método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
TW202100561A (zh) 2019-03-14 2021-01-01 美商戴氏公司 血漿胰舒血管素抑制劑及其於治療遺傳性血管水腫發作的用途
KR20220128379A (ko) 2020-01-13 2022-09-20 다케다 파머수티컬 컴패니 리미티드 소아 유전성 혈관부종 발작을 치료하기 위한 혈장 칼리크레인 억제제 및 이의 용도

Also Published As

Publication number Publication date
JP7164502B2 (ja) 2022-11-01
KR102424183B1 (ko) 2022-07-26
BR112016016916A2 (pt) 2018-01-23
DK3096798T3 (da) 2021-03-01
JP2017503820A (ja) 2017-02-02
KR20240033156A (ko) 2024-03-12
US11084884B2 (en) 2021-08-10
JP6845012B2 (ja) 2021-03-17
AU2015209481B2 (en) 2020-07-30
AU2020244370B2 (en) 2024-03-07
CA2937329A1 (en) 2015-07-30
KR20240049627A (ko) 2024-04-16
IL278062A (en) 2020-11-30
AU2015209481C1 (en) 2020-10-29
KR20220107077A (ko) 2022-08-01
WO2015112578A1 (en) 2015-07-30
IL263669A (en) 2019-01-31
EP3096798A4 (en) 2017-08-23
AU2024203436A1 (en) 2024-06-13
BR112016016916B1 (pt) 2023-12-19
IL278062B (en) 2022-06-01
ZA201605342B (en) 2020-11-25
AU2020244370A1 (en) 2020-10-29
MX387753B (es) 2025-03-18
ES2856076T3 (es) 2021-09-27
NZ761006A (en) 2023-04-28
CN116585468A (zh) 2023-08-15
AU2015209481A1 (en) 2016-08-25
EA038532B1 (ru) 2021-09-10
CN106132442B (zh) 2023-07-14
NZ723369A (en) 2022-12-23
US12384854B2 (en) 2025-08-12
MX2016009428A (es) 2017-04-13
JP2020002171A (ja) 2020-01-09
JP2023015087A (ja) 2023-01-31
CN106132442A (zh) 2016-11-16
MX2021013665A (es) 2021-12-10
JP2024170495A (ja) 2024-12-10
IL246864B (en) 2018-12-31
EP3096798B1 (en) 2020-11-25
ZA202004653B (en) 2022-01-26
KR20160122169A (ko) 2016-10-21
US20170002094A1 (en) 2017-01-05
US20210087293A1 (en) 2021-03-25
IL263669B (en) 2020-10-29
CA2937329C (en) 2022-05-31
PT3096798T (pt) 2021-02-25
EA201691470A1 (ru) 2016-12-30
EP3848057A1 (en) 2021-07-14
EP3096798A1 (en) 2016-11-30
EP3848057B1 (en) 2025-12-10
BR112016016916A8 (pt) 2018-05-02

Similar Documents

Publication Publication Date Title
IL278062B (en) Plasma kallikrein-binding proteins and their uses in the treatment of hereditary angioedema
ZA201801982B (en) Method and kit for processing hair
IL259570A (en) Combined therapy and their uses and methods
IL255463A (en) Methods and kits for treating depression
EP3282396A4 (en) Card and application program
ZA201802854B (en) Authentication methods and sysyems
EP3209298A4 (en) Compositions and methods for treating insomnia
ZA202108600B (en) Anti-tnfalpha-antibodies and functional fragments thereof
SG11202000029PA (en) Anti-tnfalpha-antibodies and functional fragments thereof
ZA201708223B (en) Endostatin fragments and variants for use in treating fibrosis
IL258863A (en) Integrin-binding peptides and their use
IL259096A (en) Peptides and methods of treating endometriosis using the same
IL261261A (en) Antibodies against tnf-alpha and functional fragments thereof
EP3220908A4 (en) Compositions and methods for treating endometriosis
IL261098A (en) Antibodies against tnf-alpha and functional fragments thereof
ZA201901942B (en) Nnif and nnif-related peptides and related methods
IL261793A (en) Anti-tnfalpha antibodies and their functional parts
EP3380468B8 (en) Bis-pyridazine compounds and their use in treating cancer
EP3273970A4 (en) Methods and materials for treating cancer
EP3331541A4 (en) Compositions and methods for treating wounds
PL3286013T3 (pl) Ulepszone podłoża zabezpieczone
GB201521209D0 (en) Title and application in german
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
HK1259160A1 (en) Bis-pyridazine compounds and their use in treating cancer
EP3270919A4 (en) Compositions and methods for treating hepatocellular carcinoma